title: Trends in resistance to penicillin and erythromycin of invasive pneumococci in Portugal.
abstract: Antimicrobial resistance of pneumococci is influenced by serotypes, antimicrobial consumption and vaccine use. Serotyping of 697 out of 1331 pneumococcal isolates, recovered in Portugal from 1994 to 2004, showed that the theoretical rate of heptavalent conjugate vaccine coverage was 91.7% and 63.6% for penicillin and erythromycin non-susceptible strains, respectively, in children up to 1 year old. The use of amoxicillin and erythromycin decreased in the vaccine period 2001-2004 (P=0.04 and P<0.01, respectively) but azithromycin usage increased in the same period (P<0.01). By using linear regression models, we evaluated the role of antimicrobial and vaccine use in the trends of resistance to penicillin and erythromycin among the isolates. The models suggest that the use of macrolides was the main factor associated with an increase of penicillin and erythromycin non-susceptible isolates from adults (P<0.01) and erythromycin non-susceptible isolates among children (P=0.006). These models also suggest that heptavalent vaccine is failing to reduce antimicrobial resistance as expected, possibly due to the increased consumption of azithromycin (P=0.04). The efficient use of new antibiotics may reverse the present trends of antimicrobial resistance.
authors: Antibiotic Resistance Unit, Centre of Bacteriology, National Institute of Health, Dr Ricardo Jorge, Lisbon, Portugal.
authors: R
authors: R
authors: Dias
authors: M
authors: M
authors: Caniça
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000658:Amoxicillin / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000494:pharmacology* / Q000627:therapeutic use; D017963:Azithromycin / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D024881:Drug Resistance, Bacterial; D004917:Erythromycin / Q000494:pharmacology* / Q000627:therapeutic use; D000069443:Heptavalent Pneumococcal Conjugate Vaccine; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D018942:Macrolides / Q000627:therapeutic use; D022401:Meningococcal Vaccines / Q000276:immunology; D008875:Middle Aged; D015233:Models, Statistical; D010406:Penicillins / Q000494:pharmacology*; D011008:Pneumococcal Infections / Q000382:microbiology*; D022242:Pneumococcal Vaccines / Q000276:immunology; D011174:Portugal; D012703:Serotyping; D013296:Streptococcus pneumoniae / Q000145:classification / Q000187:drug effects* / Q000302:isolation & purification
chemical_list: D000900:Anti-Bacterial Agents; D000069443:Heptavalent Pneumococcal Conjugate Vaccine; D018942:Macrolides; D022401:Meningococcal Vaccines; D010406:Penicillins; D022242:Pneumococcal Vaccines; D004917:Erythromycin; D000658:Amoxicillin; D017963:Azithromycin
references: Clin Infect Dis. 2000 Oct;31(4):875-80
references: 11049764
references: Antimicrob Agents Chemother. 2006 Jun;50(6):2098-105
references: 16723571
references: J Antimicrob Chemother. 2001 Oct;48(4):463-78
references: 11581224
references: Pediatr Infect Dis J. 2001 Oct;20(10):951-8
references: 11642629
references: Infection. 2001 Oct;29(5):251-6
references: 11688901
references: Emerg Infect Dis. 2002 Mar;8(3):278-82
references: 11927025
references: J Antimicrob Chemother. 2002 Oct;50(4):611-2
references: 12356811
references: Clin Microbiol Infect. 2002;8 Suppl 2:12-42
references: 12427206
references: J Antimicrob Chemother. 2002 Dec;50 Suppl S2:1-5
references: 12556427
references: J Antimicrob Chemother. 2002 Dec;50 Suppl S2:27-37
references: 12556431
references: J Antimicrob Chemother. 2002 Dec;50 Suppl S2:39-43
references: 12556432
references: J Antimicrob Chemother. 2003 Feb;51(2):409-14
references: 12562712
references: N Engl J Med. 2003 May 1;348(18):1737-46
references: 12724479
references: Lancet Infect Dis. 2004 Mar;4(3):144-54
references: 14998500
references: J Antimicrob Chemother. 2004 May;53(5):793-6
references: 15056640
references: Antimicrob Agents Chemother. 2004 Jun;48(6):2206-13
references: 15155223
references: Antimicrob Agents Chemother. 2004 Aug;48(8):2883-7
references: 15273096
references: Curr Drug Targets Infect Disord. 2004 Sep;4(3):203-6
references: 15379731
references: Rev Infect Dis. 1981 Mar-Apr;3(2):246-53
references: 7020043
references: BMJ. 1996 Aug 17;313(7054):387-91
references: 8761224
references: J Clin Microbiol. 1997 Mar;35(3):764-6
references: 9041430
references: Pediatr Infect Dis J. 1997 Apr;16(4):438-43
references: 9109156
references: Proc Natl Acad Sci U S A. 1997 Jun 10;94(12):6571-6
references: 9177259
references: Int J Med Microbiol. 2004 Oct;294(5):277-94
references: 15532987
references: J Antimicrob Chemother. 2004 Dec;54(6):1035-9
references: 15531597
references: J Antimicrob Chemother. 2004 Dec;54(6):1045-50
references: 15531598
references: Acta Med Port. 2004 Jan-Feb;17(1):49-53
references: 15636727
references: Lancet. 2005 Feb 12-18;365(9459):579-87
references: 15708101
references: Pediatr Infect Dis J. 2005 Mar;24(3):243-52
references: 15750461
references: Emerg Infect Dis. 2005 Jun;11(6):829-37
references: 15963276
references: Antimicrob Agents Chemother. 2005 Aug;49(8):3520-2
references: 16048973
references: Antimicrob Agents Chemother. 2006 Jun;50(6):2064-71
references: 16723567
references: Lancet. 2001 Jun 9;357(9271):1851-3
references: 11410197